PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayJazz Pharmaceuticals, maker of the blockbuster epilepsy drug Epidiolex, is acquiring Actio Biosciences and its lead drug in pivotal testing for a rare type of epilepsy with no FDA-approved treatments. It’s Jazz’s second epilepsy deal in the past year.
The post Jazz Pharma Expands Again in Epilepsy With $820M Actio Bio Acquisition appeared first on MedCity News.

.jpg)
2 days ago
14










English (US) ·